Finance Foggle

  Key Takeaways 🚨  FDA Warning Issued : The FDA sent WHOOP a warning letter on July 14, 2025, declaring its Blood Pressure Insights (BPI) feature an unapproved medical device . ⚖️  Regulatory Dispute : WHOOP argues BPI is a wellness tool (exempt from FDA review), while the FDA insists blood pressure measurement is inherently clinical . 💡  How BPI Works : Uses morning heart rate, HRV, and blood flow patterns (calibrated via a cuff) to estimate daily systolic/diastolic ranges, not real-time readings . ⚠️  FDA’s Safety Concerns : Inaccurate readings could delay hypertension treatment, risking stroke or heart failure . 💰  Consumer Impact : BPI is a key selling point of WHOOP’s $359/year “Life” tier. Removal could devalue the subscription . ⏳  Current Status : BPI remains active in the U.S. as WHOOP contests the FDA’s stance . The FDA-WHOOP Clash Over Blood Pressure Insights What’s Happening? On July 14, 2025, the FDA sent WHOOP a formal warning letter. ...